Trials / Conditions / Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
5 registered clinical trials studyying Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Sur NCT05987241 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Withdrawn | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer NCT03419130 | University of California, San Francisco | Phase 2 |
| Completed | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for NCT03421652 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Active Not Recruiting | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advance NCT03244384 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot NCT02812420 | M.D. Anderson Cancer Center | EARLY_Phase 1 |